Today, at all four of our wholly-owned central laboratory testing facilities (United States, Netherlands, China, and Singapore), we at Eurofins Central Laboratory, a division of Eurofins BioPharma Services, wear red with the American Heart Association to aide in uniting the world from continent to continent in effort of bringing awareness to our friends, families, and colleagues suffering from cardiovascular-related diseases (CVD). Diseases under this remit include, but are not limited to, defects at birth, heart rhythm complications, and abnormal blood vessel conditions.
United States
Netherlands
China
Singapore
According to the World Health Organization (WHO):
- Cardiovascular-related diseases are the #1 cause of death worldwide. More people die annually due to CVD than from any other cause.
- In 2016, it was estimated globally that 17.9 million people died from a cardiovascular-related disease, translating to 31% of all global deaths.
- By addressing lifestyle habits which aggravate CVD, these disease can usually become preventable.
WHO also states the following risk factors for heart disease:
- Age
- Family history
- Smoking
- Poor diet
- High blood pressure
- High blood cholesterol levels
- Diabetes
- Obesity
- Physical inactivity
- Stress
- Poor hygiene
Eurofins Central Laboratory recently provided services in support of a cardiovascular study to 10,064 randomized patients spread across 5 continents, 39 countries, and over 1,100 sites. Supported by an industry-leading Scientific Team, assays are developed and validated to meet the specific requirements of CVD Clinical Trial Programs. As our Bioanalytical Services are fully integrated in our Central Laboratory, we offer a seamless transition from the rigorous and tightly controlled environment required for primary efficacy analysis to a high-volume production testing environment under one roof.
Eurofins Central Laboratory offers prognostic, diagnostic, and exploratory biomarker analysis globally in its 4 CAP-accredited Central Laboratory locations. Biomarkers such as BNP, NT-proBNP, ANP, Toponin T or I, Creatinine phosphokinase-MB, Galectin-3, ST2, C-reactive protein, Fibrinogen, Monocytes, Lipoprotein, LDL, HDL, ApoB 100, Adiponectin, glycated hemoglobin and haptoglobin can be used either for primary efficacy analysis or for additional data to support mechanism of action claims in CVD clinical trials.
Heart defects can't be prevented. However, we at Eurofins Central Laboratory, would like to take this opportunity to offer some preventative measures to live a happy, healthy, and hearty lifestyle.
Quit smoking
Grasp control of health-related conditions such as high-blood pressure, diabetes, and high cholesterol
Exercise at least 30 minutes a day 4-5 days a week
Maintain a healthy weight
Practice good hygiene
Manage stress
Please reach out to our scientific team here so we can begin exploring the highest impact and economically sound solutions for your CVD clinical research.
Sources: